These findings are particularly important in revising the classical prognosticators in breast cancer which relied on the expression status of ERα, progesterone receptor, and HER2 as the main receptors for classifying patients into distinct molecular subtypes and predicting a response to therapy. The gene discussed is ERBB2; the disease is breast carcinoma.